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Abstract
Purpose—Cyclooxygenase-2 (COX-2) has been reported to be ubiquitously expressed in Wilms
tumor, the most common malignant renal tumor in children. However, the regulation mechanism
of COX-2 expression remains unexplored.
Materials and Methods—Quantitative real-time PCR and western blot analysis were
performed to detect COX-2 mRNA and protein expression in WiT49 cells upon the stimulation by
sphingosine-1-phosphate (S1P) as well as S1P2 and COX-2 mRNA expression in 10 fresh frozen
Wilms tumor tissues and their matched normal tissues. Overexpression, blockade and
downregulation of S1P2 were performed using adenoviral transduction, S1P2 antagonist JTE-013
and siRNA transfection, respectively. The level of prostaglandin E2 (PGE2) in WiT49 cells was
determined by gas chromatography/mass spectrometry.
Results—S1P induced COX-2 mRNA and protein expression in WiT49 cells in a concentration-
dependent manner. Overexpression of S1P2 in WiT49 cells led to a significant increase in COX-2
mRNA and protein expression as well as subsequent PGE2 synthesis. In addition, pretreatment of
those cells overexpressing S1P2 with S1P2 selective antagonist JTE-013 completely blocked S1P-
induced COX-2 protein expression. In accordance with these results, silencing of S1P2 in WiT49
cells downregulated S1P-induced COX-2 expression. Further research on 10 Wilms tumor
specimens found that S1P2 mRNA was greatly increased in Wilms tumor.
Conclusions—S1P induced COX-2 expression in Wilms tumor, and this effect was mediated by
S1P2. This finding extends the biological function of S1P2 and provides the biochemical basis for
the development of inhibitors targeting S1P/COX-2 signaling pathway.
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Cyclooxygenase (COX) is a key, rate-limiting enzyme that converts arachidonic acid into
prostaglandins (PGs). Two isoforms of COX enzymes have been characterized: COX-1,
which is constitutively expressed in most mammalian tissues,1 and COX-2, which is induced
by various factors including mitogens, hormones, serum and cytokines.2 Interestingly,
COX-2 has been found to be overexpressed in various human cancers. It plays a crucial role
in carcinogenesis through synthesis of PGs which stimulate PGs receptors with subsequent
enhancement of cellular proliferation, promotion of angiogenesis, inhibition of apoptosis
and suppression of immune responses.3 With the successful use of celecoxib, the first
approved selective COX-2 inhibitor, to reduce the formation of colorectal polyps in patients
with familial adenomatous polyposis and inhibit experimentally-induced tumorigenesis in
several animal models,4 COX-2 was proposed to be a potential molecular target for cancer
chemoprevention.
Sphingosine-1-phosphate (S1P) is an important bioactive lipid that exerts a wide variety of
cellular functions via interaction with five G protein-coupled receptors (named S1P1–5).5
Many studies have shown that S1P and its receptors are involved in diverse processes such
as angiogenesis, cardiac development, neuronal survival, immunity and recently
carcinogenesis.6, 7 Interestingly, S1P has been shown to induce COX-2 expression in some
cell types.8–13 In addition, Lee et al. found that COX-2 was ubiquitously expressed in
human primary Wilms tumors and the specific COX-2 inhibitor SC-236 suppressed tumor
growth and inhibited tumor angiogenesis in an orthotopic xenograft model.14 These findings
drove us to investigate the role of S1P regulation of COX-2 expression in Wilms tumor.
In this study, we aimed to study the regulation of COX-2 by S1P in WiT49 cells, a well-
characterized Wilms tumor cell line,15 and to determine which S1P receptor was responsible
for this effect. In addition, we studied the expression of COX-2 and its related S1P receptor
in 10 Wilms tumor specimens.
Materials and Methods
Cell culture, siRNA transfection and adenoviral transduction
WiT49 cells were cultured as described previously.15 Transfection of small interfering RNA
(siRNA) oligonucleotide duplexes to block S1P2 expression was done using Oligofectamine
reagent (Invitrogen) according to manufacturer’s instructions. The sequences of siRNA
(Dharmacon) were as follows: UACCUUGCUCUCUGGCUCU (S1P2 siRNA);
UUCUCCGAACGUGUCACGUUU (NS siRNA). For adenoviral transduction, cells were
infected with adenovirus containing GFP, S1P1 or S1P2 for 16–24 h (100 multiplicity of
infection) before different assays were done.
Quantitative real-time PCR
Total RNA was isolated from WiT49 cells treated with S1P (Biomol) under different
conditions or Wilms tumor tissues using Trizol reagent (Invitrogen) according to the
manufacturer’s protocol. Then cDNA was generated from 1 μg RNA in the presence of
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random hexamer primers, deoxynucleoside triphosphates and Moloney murine leukemia
virus reverse transcriptase (Invitrogen). Primers were designed using Primer Express™ 2.0
(Applied Biosystems) according to the software guidelines. Sequences were as follows: 5′-
GTG CAA CAC TTG AGT GGC TAT-3′ (forward) and 5′-AGC AAT TTG CCT GGT
GAA TGA T-3′ (reverse) for the COX-2 gene, 5′-GGC CTA GCC AGT TCT GAA AGC
-3′ (forward) and 5′-GCG TTT CCA GCG TCT CCT T-3′ (reverse) for the S1P2 gene, 5′-
TGCACCACCAACTGCTTAGC-3′ (forward) and 5′-
GGCATGGACTGTGGTCATGAG-3′ (reverse) for the GAPDH gene and 5′-
GACAGGATGCAGAAGGAGATTACT-3′ (forward) and 5′-
TGATCCACATCTGCTGGAAGGT-3′ (reverse) for the β-Actin gene. Real-time PCR was
performed using SYBR Green I DNA binding dye technology on an ABI Prism 7900 HT
Sequence Detection System (PE Applied Biosystems). Results were expressed relative to the
internal control gene β-Actin or GAPDH.
Western blot analysis
WiT49 cells were treated with S1P with or without JTE-013 (Tocris Bioscience) under
different conditions. Then they were washed with ice-cold PBS and homogenized in RIPA
buffer. Samples were centrifuged at 14,000 g for 20 min at 4 °C, and protein concentrations
of supernatants were determined by BCA protein assay Kit (Pierce). Equal amounts of
protein were separated on 8% SDS-PAGE and blotted to nitrocellulose membranes. The
membranes were incubated with the indicated primary antibodies (anti-COX-2 and anti-β-
Actin, both from Santa Cruz), followed by incubation with horseradish peroxidase-
conjugated secondary antibodies. Immunoreactivity was visualized by exposure to X-ray
film using Pierce ECL Western Blotting Substrate, according to the manufacturer’s
instructions.
Prostaglandin E2 (PGE2) analysis
The level of PGE2 in cell pellets was quantified by a highly precise and accurate assay
employing gas chromatography/mass spectrometry utilizing stable isotope dilution
methodology as described.16
Statistical Analysis
All experiments on cell lines were performed at least twice on separate occasions. The data
are presented as means ± SD from a representative experiment. The statistical significance
of differences between two groups was determined by Student’s t test using Microsoft Excel
software.
Results
S1P induced COX-2 expression in WiT49 cells
Previous reports have indicated that S1P signaling induces COX-2 expression. However,
little is known about this pathway in Wilms tumor. Therefore, WiT49, a well-characterized
Wilms tumor cell line,15 was utilized. After treatment of WiT49 cells with different
concentrations of S1P for 2 h, quantitative real-time PCR analysis showed that S1P induced
COX-2 mRNA expression in a concentration-dependent manner with the maximal effect
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observed at 100 nM (fig. 1, A). Western blot analysis further confirmed the increase of
COX-2 expression by S1P on the protein level (fig. 1, B). However, using FTY720
phosphate (FTY720-P), an agonist for all S1P receptors except S1P2, we did not see such an
induction (data not shown), which suggested that this effect might be mediated by S1P2.
Overexpression of S1P2 increased S1P-induced COX-2 expression and PGE2 synthesis in
WiT49 cells
To prove this notion, we overexpressed S1P2 in WiT49 cells by adenoviral transduction.
Consistent with our hypothesis, overexpression of S1P2 into WiT49 cells dramatically
increased the expression level of COX-2 mRNA and a further increase was seen with S1P
stimulation by quantitative real-time PCR analysis (fig. 2, A). Western blot analysis further
confirmed this result on COX-2 protein level while overexpression of S1P1 had no such
effect compared to that of GFP control cells (fig. 2, B). In addition, pretreatment of WiT49
cells overexpressing S1P2 with S1P2 selective antagonist JTE-013 17 completely blocked
S1P-induced COX-2 expression (fig. 2, C).
Prostaglandin E2 (PGE2) is the major prostaglandin product of COX-2 enzyme in many
human tumors.3 Functional assay measuring PGE2 synthesis showed that cells
overexpressing S1P2 contained relatively abundant PGE2 compared to GFP control cells in
which the basal level of PGE2 is undetectable in our assay system. Consistent with the data
on COX-2 mRNA and protein, stimulation with S1P further increased PGE2 synthesis in
S1P2-overexpressing cells. Moreover, it resulted in the amount of PGE2 in GFP control cells
becoming detectable (fig. 2, D).
Downregulation of S1P2 reduced S1P-induced COX-2 expression in WiT49 cells
To further confirm the role of S1P/S1P2 signaling on COX-2 expression, we used siRNA
technology to downregulate S1P2 expression in WiT49 cells. Quantitative real-time PCR
analysis proved that the siRNA against S1P2 was significantly effective in reducing the
mRNA level of S1P2 (fig. 3, A). Treatment of WiT49 cells with this S1P2 siRNA potently
inhibited S1P-induced COX-2 mRNA and protein expression (fig. 3, B and C). Taken
together, all the above data clearly demonstrated that S1P-induced COX-2 expression was
mediated by S1P2.
S1P2 mRNA was increased in Wilms tumor
Having shown the role of S1P2 in S1P-induced COX-2 expression in vitro and based on the
finding that COX-2 was extensively expressed in Wilms tumor,14, 18 we were interested in
knowing whether this pathway also exists in vivo. Therefore, quantitative real-time PCR
analysis was performed to detect the expression level of COX-2 and S1P2 mRNA in 10
Wilms tumor specimens. Compared to their matched normal tissues, COX-2 mRNA was
slightly increased in Wilms tumor specimens while S1P2 mRNA was greatly increased
(P<0.01; fig. 4), which indicated that S1P/S1P2/COX-2 pathway may also exist in vivo.
Li et al. Page 4














Wilms tumor is the most common malignant renal tumor in children. Although it has a
relatively high cure rate, which is achieved by surgery, chemotherapy and radiotherapy,
some children with tumors that harbor adverse biologic features still succumb to their
disease.19 Moreover, current therapies are usually associated with significant late sequelae.
To date, our knowledge of the mechanisms leading to Wilms tumor progression and
metastasis is limited. Therefore, a better understanding of the stimuli and signaling pathways
involved in Wilms tumor progression is needed in order to develop future therapeutic
strategy.
Recently, S1P signaling has been reported to induce COX-2 expression in different cell
types.8–13 However, it is unknown whether this effect also exists in human cancers, such as
Wilms tumor. We detected the effect of S1P on COX-2 expression in WiT49 cells and found
that S1P induced COX-2 mRNA and protein expression concentration-dependently (fig. 1).
S1P displays diverse cellular functions by interaction with its five specific receptors S1P1–5,
in which S1P1 mainly couples Gi protein while S1P2 couples G12/13 protein.5 In rheumatoid
arthritis synoviocytes, Kitano et al. found that S1P-induced COX-2 expression was sensitive
to pertussis toxin, an inhibitor of the Gi protein,11 in accordance with Kim et al.’s findings
in human amnion-derived WISH cells.10 However, in mouse embryonic fibroblast cells,
S1P-induced COX-2 expression was specifically regulated by Gα12.9 These findings
indicated that S1P-induced COX-2 expression might be cell type-specific.
To delineate which S1P receptor was responsible for S1P-induced COX-2 expression in
Wilms tumor, we used different approaches. FTY720-P, an S1P analogue that binds all S1P
receptors except S1P2, could not induce COX-2 expression suggesting that this effect might
be mediated by S1P2 signaling. Further, overexpression or downregulation of S1P2
expression either increased or decreased COX-2 mRNA and protein expression confirming
that S1P/S1P2 signaling was required for COX-2 induction (figs. 2 and 3). In addition, the
specific S1P2 antagonist JTE-013 completely blocked S1P-induced COX-2 expression in
cells overexpressing S1P2 (fig. 2, C), further confirming the requirement of S1P2 in COX-2
induction by S1P. PGE2 is the principle metabolite of COX-2 enzyme. As expected, the
cells overexpressing S1P2 produced much more PGE2 than GFP control cells. And
stimulation with S1P led to a further increase (fig. 2, D). Taken together, these data clearly
demonstrate that S1P2 was responsible for S1P-induced COX-2 expression and its
downstream molecule PGE2 synthesis in vitro.
Previous reports have shown that COX-2 was ubiquitously expressed in human Wilms
tumor.14, 18 Consistent with these findings, our study on 10 Wilms tumor specimens also
showed that COX-2 mRNA was extensively expressed in Wilms tumor specimens.
Interestingly, we also found that among the four S1P receptors (S1P1–3,5) that Wilms tumor
expressed (data not shown), S1P2 was significantly upregulated in Wilms tumor, which
indicate that S1P/S1P2/COX-2 pathway may also have physiopathological relevance in vivo.
In summary, our study for the first time clearly demonstrated that S1P induced COX-2
expression and subsequent PGE2 synthesis in WiT49 cells, and this effect was mediated by
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S1P2, which extends the biological function of S1P2 in human cancers and provides the
biochemical basis for the development of inhibitors targeting S1P/COX-2 signaling
pathway. In previous studies S1P2 was usually regarded as a negative modulator in tumor
progression.20 Here for the first time we suggest that S1P2 might act as a positive tumor
modulator and thus promote tumor progression. Further work in other human cancers will
allow us to better understand the role of S1P2 in tumor progression.
Conclusions
This study for the first time clearly demonstrated that S1P induced COX-2 expression and
subsequent PGE2 synthesis in WiT49 cells, and this effect was mediated by S1P2, which
extends the biological function of S1P2 in human cancers and provides the biochemical
basis for the development of inhibitors targeting S1P/COX-2 signaling pathway.
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S1P induced COX-2 expression in WiT49 cells. WiT49 cells were serum starved for 24 h
and then treated with different concentrations of S1P for 2 h before quantitative real-time
PCR (A) and western blot analysis (B) were done. The mRNA expression of COX-2 was
normalized to that of GAPDH and presented as means ± SD. *, P<0.05, **, P<0.01 versus
without S1P.
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Overexpression of S1P2 increased COX-2 and PGE2 synthesis in WiT49 cells. WiT49 cells
were infected with adenovirus containing GFP, S1P2 or S1P1 with MOI 100. After 16–24 h,
cells were serum starved for 24 h and then stimulated with 100 nM S1P for 2 h before
quantitative real-time PCR (A) and western blot analysis (B) were done. *, P<0.05 versus
without S1P; #, P<0.05, ##, P<0.01 versus corresponding GFP control. C, WiT49 cells
overexpressing S1P2 or GFP were serum starved and pretreated with 1 μM JTE-013 for 30
min before stimulation with 100 nM S1P for another 2 h. Then western blot analysis was
done. D, WiT49 cells were seeded at the cell density of 1x106 cells per dish (60 mm). After
attachment, they were infected with adenovirus containing S1P2 or GFP with MOI 100 for
16 h followed by serum starvation for another 24 h. Then the cells were treated with 100 nM
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S1P for 2 h and collected for PGE2 analysis. Data shown are representative of two
independent experiments.
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Downregulation of S1P2 reduced S1P-induced COX-2 expression in WiT49 cells. A, WiT49
cells were transfected with 100 nM S1P2 siRNA or NS siRNA, harvested 48 h later and
assayed for the level of S1P2 mRNA by quantitative real-time PCR. *, P<0.05 versus NS
siRNA. B and C, After transfection with S1P2 siRNA for 24 h, WiT49 cells were serum
starved for 24 h and then stimulated with 100 nM S1P for another 2 h before quantitative
real-time PCR (B) and western blot analysis (C) were done. **, P<0.01 versus without
S1P; #, P<0.05, ##, P<0.01 versus corresponding NS siRNA control.
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Relative mRNA expression of S1P2 and COX-2 in Wilms tumor and their matched normal
tissues. Quantitative real-time PCR was performed in 10 Wilms tumor tissues and their
matched normal tissues. The mRNA expression of S1P2 and COX-2 was normalized to that
of the housekeeping gene β-Actin and presented as means ± SE from 10 samples..**, P<0.01
versus that of their matched normal tissues.
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